Banban Li

434 total citations
14 papers, 301 citations indexed

About

Banban Li is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Banban Li has authored 14 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Cancer Research and 2 papers in Genetics. Recurrent topics in Banban Li's work include Circular RNAs in diseases (4 papers), MicroRNA in disease regulation (4 papers) and RNA Research and Splicing (3 papers). Banban Li is often cited by papers focused on Circular RNAs in diseases (4 papers), MicroRNA in disease regulation (4 papers) and RNA Research and Splicing (3 papers). Banban Li collaborates with scholars based in China, Sweden and Montenegro. Banban Li's co-authors include Jikui Sun, Quanfeng Ma, Jinhuan Wang, Chang Shu, Weidong Yang, Zhijuan Chen, Anling Zhang, Zhifan Jia, Guangxiu Wang and Andy Curtis and has published in prestigious journals such as Frontiers in Immunology, Molecular Cancer and Cell Death and Disease.

In The Last Decade

Banban Li

13 papers receiving 298 citations

Peers

Banban Li
Tommaso Tabaglio United States
Michael Boice United States
Adam Kosti United States
Hao Jin China
Banban Li
Citations per year, relative to Banban Li Banban Li (= 1×) peers Wenzheng Luo

Countries citing papers authored by Banban Li

Since Specialization
Citations

This map shows the geographic impact of Banban Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Banban Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Banban Li more than expected).

Fields of papers citing papers by Banban Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Banban Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Banban Li. The network helps show where Banban Li may publish in the future.

Co-authorship network of co-authors of Banban Li

This figure shows the co-authorship network connecting the top 25 collaborators of Banban Li. A scholar is included among the top collaborators of Banban Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Banban Li. Banban Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Li, Banban, et al.. (2025). Deubiquitinase TRIM44 Promotes Autophagy‐Mediated Chemoresistance in Diffuse Large B Cell Lymphoma. Hematological Oncology. 43(4). e70119–e70119. 1 indexed citations
2.
Li, Banban, et al.. (2025). Update on metformin for osteoarthritis treatment. Inflammopharmacology. 33(10). 5963–5975.
3.
Li, Banban, et al.. (2022). PTPRC Overexpression Predicts Poor Prognosis and Correlates with Immune Cell Infiltration in Pediatric Acute Myeloid Leukemia. Clinical Laboratory. 68(07/2022). 4 indexed citations
4.
Li, Banban, Wěi Li, Ying Zhou, et al.. (2021). PAK1 Mediates Bone Marrow Stromal Cell-Induced Drug Resistance in Acute Myeloid Leukemia via ERK1/2 Signaling Pathway. Frontiers in Cell and Developmental Biology. 9. 686695–686695. 12 indexed citations
5.
Wang, Yan, Dongmei Guo, Banban Li, et al.. (2021). MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1). Leukemia Research. 112. 106769–106769. 12 indexed citations
6.
Liu, Lu, Yu Hou, Ling Wang, et al.. (2021). Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia. Frontiers in Immunology. 11. 603278–603278. 8 indexed citations
7.
8.
Sun, Jikui, Quanfeng Ma, Chang Shu, et al.. (2020). MicroRNA‑301a/ZNRF3/wnt/β‑catenin signal regulatory crosstalk mediates glioma progression. International Journal of Oncology. 58(1). 45–56. 14 indexed citations
9.
Sun, Jikui, Banban Li, Chang Shu, Quanfeng Ma, & Jinhuan Wang. (2020). Functions and clinical significance of circular RNAs in glioma. Molecular Cancer. 19(1). 34–34. 136 indexed citations
10.
Sun, Jikui, Quanfeng Ma, Banban Li, et al.. (2020). RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway. Cell Death and Disease. 11(10). 31 indexed citations
11.
Sun, Jikui, Banban Li, Zhifan Jia, et al.. (2018). RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway. Journal of Neuro-Oncology. 140(1). 15–26. 33 indexed citations
12.
Sun, Jikui, Zhifan Jia, Banban Li, et al.. (2017). MiR-19 regulates the proliferation and invasion of glioma by RUNX3 via β-catenin/Tcf-4 signaling. Oncotarget. 8(67). 110785–110796. 34 indexed citations
13.
Li, Banban, et al.. (2014). [Effect of hypoxia on the growth and apoptosis of the human multiple myeloma cell lines RPMI8226].. PubMed. 35(7). 664–6. 1 indexed citations
14.
Xu, Jinfen, Banban Li, & Andy Curtis. (2014). Validating an English language teaching reflection inventory in a Chinese EFL context. System. 49. 50–60. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026